Related Experiment Videos
Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design
S Böhler1, S Saubadu, R Scheldewaert
1Synthélabo Arzneimittel GmbH, Berlin, Germany. medizin@synthelabo.de
Insights
Beta-blockers, once contraindicated for heart failure, now show promise in slowing disease progression and improving survival. The BETACAR study will further assess the benefits of betaxolol in chronic heart failure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers were historically contraindicated in heart failure due to negative inotropic effects.
- Emerging evidence suggests beta-blockers can mitigate left ventricular dilatation in heart failure patients.
- Left ventricular ejection fraction changes during beta-blocker therapy may predict patient survival.
Purpose of the Study:
- To evaluate the efficacy of betaxolol, a selective long-acting beta-blocker, in chronic heart failure (CHF).
- To compare the effects of betaxolol against carvedilol in patients with CHF.
- To further assess the beneficial effects of beta-blockade in managing chronic heart failure.
Main Methods:
- The BETACAR study is a comparative clinical trial.
- The study design involves assessing betaxolol against carvedilol.
- Participants will be patients with chronic heart failure.
Main Results:
- Data on the comparative efficacy of betaxolol and carvedilol in CHF is pending.
- The study aims to determine the impact on left ventricular dilatation and ejection fraction.
- Predictive value of ejection fraction changes for survival will be analyzed.
Conclusions:
- Further assessment of beta-blockade benefits in CHF is warranted.
- Betaxolol's potential role in managing chronic heart failure requires investigation.
- The BETACAR study will provide valuable insights into beta-blocker therapy for heart failure.
Abstract:
The use of beta-blockers in heart failure for a long time was regarded as contra-indicated because of their negative inotropic effects. Nevertheless, there is growing evidence that beta-blockers slow down the progression of left ventricular dilatation that characterizes heart failure. In addition changes in left ventricular ejection fraction after several months of beta-blocker treatment appears to have predictive value for survival. This beneficial effect of beta-blockade in chronic heart failure needs to be assessed further. The presumed benefit of beta-blockade with betaxolol (CAS 63659-18-7), a highly selective beta-blocker with long duration of action in chronic heart failure (CHF) will be assessed in BETACAR, a comparative study versus carvedilol (CAS 72956-09-3). The design of this study is provided in this article.